合一生技股份有限公司 / 2017 / Oneness Biotech has licensed out OB318, a novel drug candidate for hepatocellular carcinoma to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao.
Oneness Biotech has licensed out OB318, a novel drug candidate for hepatocellular carcinoma to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao.
